272 related articles for article (PubMed ID: 35326711)
21. Paraproteinemia and neuropathy.
Koike H; Katsuno M
Neurol Sci; 2021 Nov; 42(11):4489-4501. PubMed ID: 34529193
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy.
Eurelings M; Notermans NC; Van de Donk NW; Lokhorst HM
Muscle Nerve; 2001 Oct; 24(10):1295-302. PubMed ID: 11562908
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal gammopathy-associated peripheral neuropathies: Uncovering pearls and challenges.
Gonçalves TAP; Donadel CD; Frezatti RSS; Garibaldi PMM; Calado RT; Marques Junior W; Tomaselli PJ
J Peripher Nerv Syst; 2024 Jun; 29(2):161-172. PubMed ID: 38873841
[TBL] [Abstract][Full Text] [Related]
24. [Autoimmune neuropathy].
Hansen PR
Ugeskr Laeger; 1989 Oct; 151(44):2870-3. PubMed ID: 2686140
[TBL] [Abstract][Full Text] [Related]
25. Spinal Cord Impairment in Anti-Mag Neuropathy: Evidence from Somatosensory Evoked Potentials.
Boscarino M; Lanzone J; Ricci L; Tombini M; Di Lazzaro V; Assenza G
Brain Sci; 2020 May; 10(5):. PubMed ID: 32397154
[TBL] [Abstract][Full Text] [Related]
26. Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody.
Kawagashira Y; Koike H; Ohyama K; Hashimoto R; Iijima M; Adachi H; Katsuno M; Chapman M; Lunn M; Sobue G
J Neurol Sci; 2015 Jan; 348(1-2):67-73. PubMed ID: 25467141
[TBL] [Abstract][Full Text] [Related]
27. Polyneuropathy associated with IgM monoclonal gammopathy: a review. Clinical, electrophysiological and pathological features.
Leger JM; Vaunaize J
Nouv Rev Fr Hematol (1978); 1990; 32(5):303-6. PubMed ID: 1965990
[TBL] [Abstract][Full Text] [Related]
28. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy.
Briani C; Visentin A; Salvalaggio A; Cacciavillani M; Trentin L
Eur J Neurol; 2019 Feb; 26(2):371-375. PubMed ID: 30315672
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.
Chaudhry HM; Mauermann ML; Rajkumar SV
Mayo Clin Proc; 2017 May; 92(5):838-850. PubMed ID: 28473042
[TBL] [Abstract][Full Text] [Related]
30. Anti-myelin-associated glycoprotein neuropathy.
Steck AJ; Stalder AK; Renaud S
Curr Opin Neurol; 2006 Oct; 19(5):458-63. PubMed ID: 16969155
[TBL] [Abstract][Full Text] [Related]
31. Advances in the Treatment of Paraproteinemic Neuropathy.
Nobile-Orazio E; Bianco M; Nozza A
Curr Treat Options Neurol; 2017 Oct; 19(12):43. PubMed ID: 29034435
[TBL] [Abstract][Full Text] [Related]
32. Anti-MAG associated cerebellar ataxia and response to rituximab.
Zis P; Rao DG; Hoggard N; Sarrigiannis PG; Hadjivassiliou M
J Neurol; 2018 Jan; 265(1):115-118. PubMed ID: 29159464
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal gammopathy and neuropathy.
Ramchandren S; Lewis RA
Curr Opin Neurol; 2009 Oct; 22(5):480-5. PubMed ID: 19625962
[TBL] [Abstract][Full Text] [Related]
34. Treatment of immune-mediated, dysimmune neuropathies.
Finsterer J
Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
[TBL] [Abstract][Full Text] [Related]
35. [Polyneuropathy associated with monoclonal gammapathy: treatment perspectives].
Leger JM; Chassande B; Bombelli F; Viala K; Musset L; Neil J
Bull Acad Natl Med; 2009 May; 193(5):1099-110; discussion 1110-1. PubMed ID: 20120390
[TBL] [Abstract][Full Text] [Related]
36. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance.
Castillo JJ; Callander NS; Baljevic M; Sborov DW; Kumar S
Am J Hematol; 2021 Jul; 96(7):846-853. PubMed ID: 33709474
[TBL] [Abstract][Full Text] [Related]
37. Systemic manifestations of monoclonal gammopathy.
Decaux O; Laurat E; Perlat A; Cazalets C; Jego P; Grosbois B
Eur J Intern Med; 2009 Sep; 20(5):457-61. PubMed ID: 19712843
[TBL] [Abstract][Full Text] [Related]
38. Polyneuropathies associated with IgM monoclonal gammopathies.
Kelly JJ; Adelman LS; Berkman E; Bhan I
Arch Neurol; 1988 Dec; 45(12):1355-9. PubMed ID: 2461693
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.
Latov N
Nat Rev Neurol; 2014 Aug; 10(8):435-46. PubMed ID: 24980070
[TBL] [Abstract][Full Text] [Related]
40. Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies.
Galassi G; Tondelli M; Ariatti A; Benuzzi F; Nichelli P; Valzania F
Int J Neurosci; 2017 May; 127(5):439-447. PubMed ID: 27188752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
